To include your compound in the COVID-19 Resource Center, submit it here.

$2.5B of leverage magic

If the acquisition of Talecris Biotherapeutics Inc. by CSL Ltd. goes through, investors Cerberus Capital Management and Ampersand Ventures will make more than $2.5 billion from an investment in the plasma-derived therapeutics company by loading it up with debt and then selling it for a profit.

Talecris Holdings, comprised of Cerberus and Ampersand, set up Talecris Biotherapeutics to acquire the plasma products business of Bayer AG for $324.8 million, including transaction costs, in 2005. With net of $20.9 million in acquired liabilities, Talecris actually paid $303.5 million in cash and 1 million in

Read the full 921 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers